Compass Pathways is positioned to leverage regulatory tailwinds and compelling clinical data, despite broader skepticism and high cash burn in the psychedelic biotech sector. The company has a financial cushion with cash reserves of $165.1 million, providing 4-6 quarters of runway before needing additional capital. COMP360 shows promise in treating treatment-resistant depression and PTSD, with significant clinical trial results and potential long-term economic benefits.
Shares of Compass (COMP -8.18%), the nation's largest real estate brokerage, were climbing this week after the company delivered better-than-expected results in its fourth-quarter earnings report and gained market share in a challenging real estate environment.
Does Compass, Inc. (COMP) have what it takes to be a top stock pick for momentum investors? Let's find out.
I recommend a hold rating for Compass due to concerns about high mortgage rates and potential regulatory risks despite strong execution. COMP reported ~$1.4 billion in revenue, driven by 25.9% y/y growth and market share gains, with strong agent retention and transaction growth. The private inventory strategy shows promise, but regulatory scrutiny and high mortgage rates could impact COMP's growth trajectory.
Compass (COMP) could be a great choice for investors looking to buy stocks that have gained strong momentum recently but are still trading at reasonable prices. It is one of the several stocks that made it through our 'Fast-Paced Momentum at a Bargain' screen.
Stellantis is pausing work on its next-generation Jeep Compass compact SUV including retooling a plant in Canada designated to build the vehicle, the company said Thursday.
Shares of Compass soared ~10% after reporting Q4 results, showcasing acceleration in growth, 65bps of y/y market share expansion, and significant margin gains. Compass continues to outperform the real estate market, expanding into new regions and acquiring Christie's real estate division, boosting its market share and growth potential. The company's Q4 revenue surged 26% y/y to $1.38 billion, with organic growth contributing 21% y/y, far outpacing the broader industry (where transaction growth was just shy of 7% y/y).
Compass, Inc. (NYSE:COMP ) Q4 2024 Earnings Conference Call February 18, 2025 5:00 PM ET Company Participants Soham Bhonsle - Head of IR Robert Reffkin - Founder & CEO Kalani Reelitz - CFO Conference Call Participants Jason Helfstein - Oppenheimer Christopher Kuntarich - UBS Bernie McTernan - Needham Ryan McKeveny - Zelman & Associates Michael Ng - Goldman Sachs Operator Thank you for standing by. And at this time, I would like to welcome everyone to today's Compass Inc. Q4 and Full Year 2024 Financial Results Conference Call.
Compass, Inc. (COMP) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.09. This compares to loss of $0.17 per share a year ago.
Compass stock price has done well in the past few months. Most recently, it has risen in the last five consecutive weeks and is sitting at its highest level since June 2022.
COMP's fourth-quarter performance is expected to have benefited from recent launches of tools in its technology platform amid seasonal pressure seen each year.
Compass Minerals International, Inc. CMP reported weaker-than-expected first-quarter adjusted EPS results and cut its FY25 salt segment revenue guidance, after the closing bell on Monday.